Skip to main content
Premium Trial:

Request an Annual Quote

Genomics England, AI Startup Collaborate on Immunotherapy

NEW YORK (GenomeWeb) – Genomics England said today that it has enlisted a startup maker of artificial intelligence in a long-term partnership meant to increase patient access to immunotherapies, monitor treatment effectiveness, and identify resistance to these advanced cancer drugs.

As part of the partnership, Cambridge Cancer Genomics — known as — is joining the Discovery Forum, a Genomics England-led collaboration platform for genomics researchers in the UK. also will contribute its liquid biopsy technology and a sequencing panel that measures tumor mutational burden to assess treatment resistance to immunotherapy drugs.

"Through genomic analysis of longitudinal liquid biopsy samples collected on a bi-weekly basis, we are able to detect the signals of resistance and relapse much earlier than standard of care. In this project, we hope to extend this technology to a new class of breakthrough cancer medicines," Chief Scientific Officer Nirmesh Patel said in a statement.